Humana Inc. (NYSE:HUM) Shares Sold by Stevens Capital Management LP

Stevens Capital Management LP reduced its position in shares of Humana Inc. (NYSE:HUM) by 60.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 2,733 shares of the insurance provider’s stock after selling 4,132 shares during the quarter. Stevens Capital Management LP’s holdings in Humana were worth $1,251,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of HUM. Meritage Portfolio Management grew its holdings in Humana by 83.9% in the 4th quarter. Meritage Portfolio Management now owns 32,389 shares of the insurance provider’s stock valued at $14,828,000 after buying an additional 14,778 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Humana by 4.2% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,731 shares of the insurance provider’s stock worth $1,250,000 after buying an additional 111 shares during the period. Atria Wealth Solutions Inc. grew its position in Humana by 10.8% during the fourth quarter. Atria Wealth Solutions Inc. now owns 3,157 shares of the insurance provider’s stock valued at $1,446,000 after acquiring an additional 307 shares during the period. Alaska Permanent Fund Corp purchased a new stake in Humana during the fourth quarter valued at about $4,573,000. Finally, Watershed Asset Management L.L.C. lifted its stake in shares of Humana by 18.0% in the 4th quarter. Watershed Asset Management L.L.C. now owns 609 shares of the insurance provider’s stock valued at $279,000 after purchasing an additional 93 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Down 1.8 %

HUM stock traded down $5.51 during midday trading on Friday, reaching $305.90. The company had a trading volume of 1,212,671 shares, compared to its average volume of 1,994,928. The company has a 50 day moving average of $328.56 and a two-hundred day moving average of $395.71. The company has a market capitalization of $36.91 billion, a P/E ratio of 19.18, a PEG ratio of 1.85 and a beta of 0.45. Humana Inc. has a 1 year low of $299.23 and a 1 year high of $541.21. The company has a current ratio of 1.67, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The firm had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter last year, the firm earned $9.38 earnings per share. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, equities research analysts expect that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.16%. Humana’s dividend payout ratio is currently 22.04%.

Insider Activity at Humana

In other Humana news, Director Jorge S. Mesquita bought 545 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was bought at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the transaction, the director now directly owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Wells Fargo & Company dropped their target price on shares of Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research report on Monday, April 8th. Stephens reduced their price objective on Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a research note on Friday, January 26th. StockNews.com downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 26th. Royal Bank of Canada cut their price target on Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Argus lowered Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Eleven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Humana currently has an average rating of “Hold” and a consensus target price of $433.74.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.